ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

Oncogene

Volumn 35, Issue 24, 2016, Pages 3201-3208

  Van Geldermalsen, M ^a,b   Wang, Q ^a,b   Nagarajah, R ^a,b   Marshall, A D ^a,b   Thoeng, A ^a,b   Gao, D ^a,b   Ritchie, W ^a,b   Feng, Y ^a,b   Bailey, C G ^a,b   Deng, N ^c,d   Harvey, K ^c,e   Beith, J M ^b,f   Selinger, C I ^e   O'Toole, S A ^b,c,e   Rasko, J E J ^a,b,e   Holst, J ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Chris o'Brien Lifehouse ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ALANINE SERINE CYSTEINE PREFERRING TRANSPORTER 2; CELL SURFACE PROTEIN; GLUTAMINE; MYC PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; MINOR HISTOCOMPATIBILITY ANTIGEN; SLC1A5 PROTEIN, HUMAN;

ARTICLE; BASAL LIKE BREAST CANCER; BIOLUMINESCENCE; CANCER GROWTH; CANCER PATIENT; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BASAL CELL CARCINOMA; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

AMINO ACID TRANSPORT SYSTEM ASC; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GLUTAMINE; HETEROGRAFTS; HUMANS; MICE; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS, BASAL CELL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84975109732     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.381     Document Type: Article

References (47)

1. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-1927.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
4. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
6. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J et al. Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
7. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
8. Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 2010; 96: 103-110.
9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
10. Kim S, Kim do H, Jung WH, Koo JS. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer 2013; 20: 339-348.
11. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triplenegative breast tumor therapeutic target. Cancer Cell 2013; 24: 450-465.
12. Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch 2004; 447: 469-479.
13. Kekuda R, Prasad PD, Fei YJ, Torres-Zamorano V, Sinha S, Yang-Feng TL et al. Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line. J Biol Chem 1996; 271: 18657-18661.
14. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350.
15. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349-358.
16. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
17. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science 2014; 345: 1250256.
18. Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M et al. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer 2014; 135: 1060-1071.
19. Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 2013; 19: 560-570.
20. Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X et al. Targeting SLC1A5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer 2015; 137: 1587-1597.
21. Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol 2015; 236: 278-289.
22. Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013; 122: 3521-3532.
23. Esslinger CS, Cybulski KA, Rhoderick JF. Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg Med Chem 2005; 13: 1111-1118.
24. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 2014; 13: 890-901.
25. Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet 2011; 7: e1002229.
26. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171.
27. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS One 2013; 8: e74157.
28. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
29. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 2007; 293: C55-C63.
30. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V et al.,rogen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 2011; 71: 7525-7536.
31. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010; 141: 290-303.
32. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496-1501.
33. Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: G467-G478.
34. Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci USA 2008; 105: 18507-18512.
35. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
36. Puca R, Nardinocchi L, Givol D, D'Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 2010; 29: 4378-4387.
37. Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH. PUMA-and Bax-induced autophagy contributes to apoptosis. Cell Death Differ 2009; 16: 1135-1145.
38. Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell 2015; 27: 354-369.
39. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010; 15: 39-48.
40. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest 2014; 124: 398-412.
41. Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, tumor development. J Natl Cancer Inst 2013; 105: 1463-1473.
42. Ren P, Yue M, Xiao D, Xiu R, Gan L, Liu H et al. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol 2015; 235: 90-100.
43. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012; 22: 631-644.
44. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
45. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105: 18782-18787.
46. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L et al. Targeting glutaminolysis has anti-leukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 2015; 126: 1346-1356.
47. Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 2010; 9: 299.